0000000000985083

AUTHOR

Nils Eiel Steen

showing 2 related works from this author

Higher vitamin B12 levels in neurodevelopmental disorders than in healthy controls and schizophrenia

2020

Recent studies suggest that both high and low levels of vitamin B12 (vitB12) may have negative health impacts. We measured VitB12 in patients with the Neurodevelopmental disorders (ND) (n = 222), comprised of Autism Spectrum Disorders, specific Developmental disorders, and Intellectual Disability (aged 2-53 years), schizophrenia (n = 401), and healthy controls (HC) (n = 483). Age-and gender-adjusted vitB12 z-scores were calculated by comparisons with a reference population (n = 76 148). We found higher vitB12 in ND (median 420 pmol/L, mean z-score: 0.30) than in HC (316 pmol/L, z-score: 0.06, P < .01) and schizophrenia (306 pmol/L, z-score: -0.02, P < .001), which was significant after adju…

AdultMale0301 basic medicinemedicine.medical_specialtyAdolescentRenal functionBiochemistryCobalaminHemoglobinsYoung Adult03 medical and health scienceschemistry.chemical_compoundFolic Acid0302 clinical medicineInternal medicineIntellectual disabilityLeukocytesGeneticsHumansMedicineIn patientVitamin B12ChildMolecular Biologybusiness.industryVitamin B 12 DeficiencyMiddle Agedmedicine.diseaseVitamin B 12030104 developmental biologyEndocrinologychemistryNeurodevelopmental DisordersSchizophreniaCase-Control StudiesChild PreschoolDietary SupplementsSchizophreniaAutismFemaleHemoglobinbusiness030217 neurology & neurosurgeryBiotechnologyThe FASEB Journal
researchProduct

Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative

2019

Abstract Background Lithium is recommended as a first line treatment for bipolar disorders. However, only 30% of patients show an optimal outcome and variability in lithium response and tolerability is poorly understood. It remains difficult for clinicians to reliably predict which patients will benefit without recourse to a lengthy treatment trial. Greater precision in the early identification of individuals who are likely to respond to lithium is a significant unmet clinical need. Structure The H2020-funded Response to Lithium Network (R-LiNK; http://www.r-link.eu.com/) will undertake a prospective cohort study of over 300 individuals with bipolar-I-disorder who have agreed to commence a …

medicine.medical_specialtyLithium (medication)[SDV]Life Sciences [q-bio]Psychological interventionOmicsNeuroimagingReviewLithiumDigitallcsh:RC321-57103 medical and health sciences0302 clinical medicinemedicineProspective cohort studyIntensive care medicinelcsh:Neurosciences. Biological psychiatry. NeuropsychiatryBiological PsychiatryPersonalizationbusiness.industrylcsh:QP351-495ResponseActigraphyPrecisionOmicsActigraphy3. Good health030227 psychiatryPsychiatry and Mental healthlcsh:Neurophysiology and neuropsychologyPhenotypeMoodTolerabilityBipolarBiomarker (medicine)business030217 neurology & neurosurgerymedicine.drugInternational Journal of Bipolar Disorders
researchProduct